Medical/Pharmaceuticals
VS Pharmtech Boosts Cancer Treatment Efficacy Without Adding Toxicity
SEOUL, South Korea, Nov. 6, 2026 /PRNewswire/ -- Cancer drugs keep improving, but their limits remain. When antibody therapies first emerged, only a fraction of patients benefited, and small-molecule anticancer drugs often carry severe toxicity. Rather than developing a new anticancer drug, Park ...
2026-11-07 01:00
2275
OncoC4 Reports Encouraging Phase 1/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026
— 33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks in patients with PD-(L)1-resistant/refractory NSCLC — — Preliminary efficacy and safety results support further development of cesalatamig monotherapy — ROCKVILLE, Md., Nov. 6, 2026 /P...
2026-11-06 22:30
7749
Neuroendocrine Cancer Day: The Cancer Hiding in Plain Sight
SYDNEY, Australia, Nov. 6, 2026 /PRNewswire/ -- Ahead of Neuroendocrine Cancer
Day on 10 November,NeuroEndocrine Cancer Australia
2026-11-06 14:00
1669
Lynk Pharmaceuticals Announces NMPA Acceptance of New Drug Application for Zemprocitinib in the Treatment of Rheumatoid Arthritis
SHANGHAI and HANGZHOU, China and BOSTON, Nov. 6, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, announced that the New Drug Application (NDA) for its core product, zemp...
2026-11-06 12:30
2820
Fosun International Receives "ESG & Corporate Sustainability Excellence Award" from Hong Kong Economic Journal
HONG KONG, Nov. 6, 2026 /PRNewswire/ -- On 5 November 2026, Hong Kong Economic Journal (HKEJ), one of Hong Kong's most influential Chinese financial publications, hosted the "ESG & Sustainability Awards of Excellence 2026" ceremony. At the event, Fosun International received the "ESG & Corporate ...
2026-11-06 09:00
3623
Antengene Announces First Patient Dosed in Phase I ATTRACT Study Evaluating ATG-201 (CD19 × CD3 TCE) for B Cell-Mediated Autoimmune Diseases
SHANGHAI and HONG KONG, Nov. 6, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dise...
2026-11-06 08:30
3047
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENRICH and ENHANCE Studies at AASLD 2026, Supporting BRII-179-Based Priming and Enrichment Strategy for HBV Functional Cure
* Data across five Phase 2 studies of BRII-179, including ENSURE, ENRICH and ENHANCE, support its potential role in priming HBV-specific immune responses and improving functional cure rates with siRNA-based therapies * ENRICH prospectively reproduced the BRII-179 priming effect previously obs...
2026-11-06 08:00
4581
ABEC Launches ATB™-2100 Platform to Transform Advanced Therapy Manufacturing
BETHLEHEM, Pa., Nov. 5, 2026 /PRNewswire/ -- ABEC, a global leader in engineered solutions and services for biopharmaceutical manufacturing, today announced the commercial launch of the ATB™-2100 Advanced Therapy Bioreactor, a breakthrough single-use cell expansion technology designed to address ...
2026-11-05 23:11
2026
Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards
Recognition Highlights Kazia's Focus on Overcoming Treatment Resistance in
Cancer
SYDNEY, Nov. 5, 2026 /PRNewswire/ -- Kazia Therapeutics Limited
2026-11-05 20:00
1991
NORROY BIOSCIENCE Showcased 11 Research Presentations at EANM' 26, Advancing Radiopharmaceutical Innovation and Global Ecosystem Collaboration
WUXI, China, Nov. 5, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a late-stage clinical biotechnology company focused on innovative targeted radiopharmaceuticals, today announced that its proprietary pipelines were featured in eight Top Rated Oral Presentations (TROP) and three e-posters at ...
2026-11-05 18:00
2342
Fosun Marks Ninth Year at CIIE, Guo Guangchang Calls for Bringing More Innovation to China and Taking Chinese Innovation Global
HONG KONG, Nov. 5, 2026 /PRNewswire/ -- On 5 November 2026, the 9th China International Import Expo (CIIE) opened at the National Exhibition and Convention Center (Shanghai). This year's expo has convened participants from 162 countries, regions, and international organizations, featuring more th...
2026-11-05 16:46
3498
Dizal to Present Latest Clinical Data at ASH 2026
* Golidocitinib monotherapy showed high and durable response in adults with secondary HLH, to be featured in an oral presentation. * Two oral presentations showing superior clinical benefits of birelentinib, as a single agent or in combination with a BCL2 inhibitor, in 1st line CLL/SLL SHANGH...
2026-11-05 16:16
2117
Harbour BioMed Appoints Ms. Vivian Feng as Head of External Collaboration
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 5, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced t...
2026-11-05 14:57
2041
Telix Joins Thera4Care with TLX400-Tx to Accelerate Translation of Next Generation FAP-Targeting Theranostics
* Thera4Care is an initiative aimed at establishing an integrated theranostics ecosystem to broaden patient access in Europe * Telix's fibroblast activation protein (FAP) targeting therapy candidate (TLX400-Tx) has been selected for evaluation with terbium-161 based on clinical potential and ...
2026-11-05 13:30
2744
Abbott and Novo expand partnership to launch Plosbrio® broadening access to semaglutide for advanced diabetes care across Asia Pacific
* The collaboration combines Novo's leadership in diabetes care medicines and GLP-1 therapies with Abbott's extensive healthcare and commercial footprint across the region * Abbott will promote and distribute Plosbrio® (semaglutide) across a number of Asia Pacific countries, helping expand ac...
2026-11-05 13:00
6672
Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer
HONG KONG, Nov. 4, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) has been granted Priority Review by China's National Medical Products Adm...
2026-11-05 12:19
2651
NCCN and Viet Nam National Cancer Hospital Expand Collaboration to Advance Cancer Care Resources in Vietnam
NCCN and Viet Nam National Cancer Hospital sign agreement to enhance ongoing guideline adaptation efforts with the inclusion of additional hematologic and solid tumor information. HANOI, Vietnam, Nov. 5, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) today announced the...
2026-11-05 10:06
3704
ONE OF THE WORLD'S FIRST PERSONALISED BRAIN STIMULATION STUDIES SHOWS PROMISE FOR SEVERE OCD WITH NUH AND NUS MEDICINE EXTENDING THE APPROACH TO DEPRESSION AND ANXIETY
Building on an established NUH–NUS Medicine collaboration, the work combines clinical expertise and cutting‑edge neuroimaging to improve outcomes for patients who have not responded to standard treatments SINGAPORE, Nov. 4, 2026 /PRNewswire/ -- Mental health treatments such as transcranial magne...
2026-11-05 08:05
2066
Illumina selected to help bring precision medicine into everyday healthcare in Singapore
SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare system SINGAPORE, Nov. 5, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) announced it has been selec...
2026-11-05 07:00
2126
Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
* First clinical data for dapolsertib monotherapy: initial results from the Phase II JASPIS-01 study of dapolsertib (MEN1703), a first-in-class oral dual PIM/FLT3 kinase inhibitor, in patients with relapsed/refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL) who have exhausted avail...
2026-11-05 02:31
3554
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1168 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1129 media titles]
2026-11-05 06:52Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
H.E. Ahmed Al-Khateeb, Saudi Minister of Tourism, Inaugurates Saudi Land at WTM London 2026, Reinforcing Saudi's Commitment to Global Travel Trade
[Picked up by 1067 media titles]
2026-11-04 07:31
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
61397
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
56941
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
54475
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
23939
